

HellerEhrman

ATTORNEYS

Facsimile Transmittal

275 Middlefield Road
Menlo Park, CA 94025-3506
Main (650) 324-7000
Fax (650) 324-0638

To: Examiner Fozia Hamud, USPTO
Telephone:

Fax: 703/746-5097

From: Daphne Reddy
Telephone: (650) 324-7037
Direct Fax: (650) 324-0638

No. of Pages: 27 (including cover)
Date: November 17, 2003

39780-1618 (7041)

Message:

Re: U.S. Patent Application No. 09/903,925
Title: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
ACIDS ENCODING THE SAME
Filed: July 11, 2001
Our Reference No.: 39780-1618P2C49

Please see attached.

H:\Fax Cover Sheets\USPTO.doc
11/17/03 12:04 PM Q

The information contained in this communication is intended only for the use of the addressee and may be confidential, may be attorney-client privileged and may constitute inside information. Unauthorized use, disclosure or copying is strictly prohibited, and may be unlawful. If you have received this communication in error or you have not received all pages, please call the sender immediately at (650) 324-7000.

Heller Ehrman White & McCulliffe LLP www.hewm.com

San Francisco Silicon Valley Los Angeles San Diego Seattle Portland Anchorage New York Washington, D.C. Madison, WI
Hong Kong Singapore Affiliated Offices: Milan Paris Rome

THE UNITED STATES PATENT AND TRADEMARK OFFICE
ACKNOWLEDGMENT AND RECEIPT FOR FILING

Applicant: Ashkenazi, et al. Serial No. 09/903,925
Filing Date: July 11, 2001 Examiner Fozia M. Hamud
Title: SECRETED AND TRANSMEMBRANE POLYPEPTIDES
AND NUCLEIC ACIDS ENCODING THE SAME

- ☒ RCE Transmittal;
- ☒ Preliminary Amendment;
- ☒ Declaration of Dr. Ashkenazi with Exhibit A attached;
- ☒ Petition for 2-month EOT to file;
- ☒ Copy of application entitled "Compositions and Methods for the Treatment of Tumors"; and
- ☒ Check No. 126271 in the amount of \$1,160.00 for two-month extension of time and RCE filing fees.

Attorney Docket No.: 39780-1618P2C49
Date: September 22, 2003
GRD/car

VIA EXPRESS MAIL NO. EV346725698US

RECEIVED BY THE UNITED STATES PATENT OFFICE



PTO/SB/30 (3/2000)
Approved for Use through xx/xx/xxxx, OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

REQUEST FOR CONTINUED EXAMINATION (RCE) TRANSMITTAL

Subsection (b) of 35 U.S.C. §132, effective on May 29, 2000, provides for continued examination of a utility or plant application filed on or after June 8, 1995.


See the American Inventors Protection Act of 1999 (AIPA).

Application Number	09/903,925
Filing Date	July 11, 2001
First Named Inventor	Ashkenazi, et al.
Group Art Unit	1647
Examiner Name	Fozia M. Hamud
Attorney Docket Number	39780-1618P2C49

This is a Request for Continued Examination (RCE) under 37 C.F.R. §1.114 of the above-identified application.
NOTE: 37 C.F.R. § 1.114 is effective on May 29, 2000. If the above-identified application was filed prior to May 29, 2000, applicant may wish to consider filing a continued prosecution application (CPA) under 37 C.F.R. § 1.53(d) (PTO/SB/29) instead of a RCE to be eligible for the patent term adjustment provisions of the AIPA. See Changes to Application Examination and Provisional Application Practice, Interim Rule, 65 Fed. Reg. 14865 (Mar. 20, 2000), 1233 Off. Gaz. Pat. Office 47 (Apr. 11, 2000), which established RCE practice.


1.	Submission required under 37 C.F.R. §1.114.
a.	<input type="checkbox"/> Previously submitted
i.	<input type="checkbox"/> Consider the amendment(s)/reply under 37 C.F.R. §1.116 previously filed on (Any unentered amendment(s) referred to above will be entered)
ii.	<input type="checkbox"/> Consider the arguments in the Appeal Brief or Reply Brief previously filed on
iii.	<input type="checkbox"/> Other
b.	<input checked="" type="checkbox"/> Enclosed
i.	<input checked="" type="checkbox"/> Preliminary Amendment
ii.	<input checked="" type="checkbox"/> Declaration(s) of Avi Ashkenazi, Ph.D., with Exhibit A;
iii.	<input type="checkbox"/> Information Disclosure Statement (IDS)
iv.	<input checked="" type="checkbox"/> Other: Copy of patent application entitled "Compositions and Methods for the Treatment of Tumor".
2.	Miscellaneous
a.	<input type="checkbox"/> Suspension of action on the above-identified application is requested under 37 C.F.R. § 1.163(c) for a period of _____ months. (Period of suspension shall not exceed 3 months; Fee under 37 C.F.R. § 1.17(f) required)
b.	<input type="checkbox"/> Other
3.	Fees The RCE fee under 37 C.F.R. §1.17(e) is required by 37 C.F.R. § 1.114 when the RCE is filed.
a.	<input checked="" type="checkbox"/> The Director is hereby authorized to charge the following fees, or credit any overpayments to Deposit Account No. 08-1641 (Docket No. 08-1641)
i.	<input checked="" type="checkbox"/> RCE fee required under 37 C.F.R. § 1.17(e) (Filing fee = \$750.00)
ii.	<input checked="" type="checkbox"/> Extension of time fee (37 C.F.R. §§ 1.136 and 1.17) (2 month EOT = \$410.00)
iii.	<input type="checkbox"/> Other
b.	<input checked="" type="checkbox"/> Check No. <u>126271</u> in the amount of \$1,160.00 enclosed.
c.	<input type="checkbox"/> Payment by credit card (Form PTO-2036 enclosed)

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

Name (Print/Type)	Ginger R. Dreger, Esq.	Registration No. (Attorney/Agent)	33,055
Signature		Date	September 22, 2003

CERTIFICATE OF MAILING (37CFR 1.10 (a))

CERTIFICATE OF MAILING BY "EXPRESS MAIL" - Rule 10: I hereby certify that this correspondence is being deposited on September 22, 2003 with the U.S. Postal Service "Express Mail Post Office to Addressee" under 37 C.F.R. 1.10 as Express Mail No. EY34872589BUS addressed to: Mail Stop: Box RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Name (Print/Type)	Cheryl Rogers
Signature	
Date	September 22, 2003

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND FEES AND COMPLETED FORMS TO THE FOLLOWING ADDRESS: Mail Stop _____, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.